Fulzerasib

DB21609InvestigationalSmall molecule

Fulzerasib is a small molecule drug. The usage of the INN stem '-rasib' in the name indicates that Fulzerasib is a Ras protein inhibitor. Fulzerasib is under investigation in clinical... Fulzerasib is under investigation in clinical trial NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic...

Mechanism: Pharmacologically active on GTPase KRas
Curator reviewed
Formula / weight: C₃₃H₃₂ClFN₆O₄ · 631.11 g/mol (avg)
Code names: GFH-925 · IBI-351

Resolves to

Compound

UNII6D5B7F245WCAS2641747-54-6

Structure

InChIKeyBRWVQEWFJJFLIQ-MGBGTMOVSA-NSMILESCC(C)C1=C(N2C(=O)C3=C(N4CCN(C[C@]4(C)C(=O)N3C)C(=O)C=C)C3=CC(Cl)=C(N=C23)C2=C(F)C=CC=C2O)C(C)=CC=N1

Targets

P01116KRAS

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Fulzerasib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account